Top Markets
#1 QuantixAI QuantixAI +102.94%
#2 MetaDAO MetaDAO +28.44%
#3 龙虾 (Lobster) 龙虾 (Lobster) +27.94%
#4 Rain Rain +23.22%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +19.58%
#6 Bedrock Bedrock +18.45%
#7 Pons Pons +18.33%
#8 Prom Prom +15.79%
#9 Humanity Humanity +14.45%
#10 Stacks Stacks +11.76%
Coin of the day
QuantixAI QuantixAI
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Heidelberg Pharma AG Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA
Classifica tra le azioni #20133
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Prezzo delle azioni
$2.99
Capitalizzazione di mercato
$139.84M
Variazione (1 giorno)
-0.40%
Variazione (1 anno)
-41.27%
Paese
DE
Scambia Heidelberg Pharma AG (HPHA)

Categoria

Healthcare
Il prezzo HPHA con la capitalizzazione del mercato della B
Heidelberg Pharma AG Heidelberg Pharma AG
HPHA
$2.99
Capitalizzazione di mercato di Heidelberg Pharma AG(HPHA)
Capitalizzazione di mercato: $139.84M
A partire dal August 2026, Heidelberg Pharma AG ha una capitalizzazione di mercato pari a $139.84M. Questo rende Heidelberg Pharma AG la 20133rd azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Heidelberg Pharma AG dal 2006 al 2026
HPHA in paragone con la classifica dei più popolari stocks
Il prezzo per HPHA Attivo B Capitalizzazione del mercato a B Risultati
Heidelberg Pharma AG Heidelberg Pharma AG
$110,133 $139.84M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.152T +3,684,359.38%
Heidelberg Pharma AG Heidelberg Pharma AG
$96,977.21 $139.84M
Apple Inc. Apple Inc.
AAPL
$4.537T +3,244,249.43%
Heidelberg Pharma AG Heidelberg Pharma AG
$89,101.65 $139.84M
Alphabet Inc. Alphabet Inc.
GOOG
$4.169T +2,980,774.60%
Heidelberg Pharma AG Heidelberg Pharma AG
$77,853.95 $139.84M
Microsoft Corporation Microsoft Corporation
MSFT
$3.642T +2,604,485.26%
Heidelberg Pharma AG Heidelberg Pharma AG
$59,949.55 $139.84M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.805T +2,005,497.91%